Drug intelligence / Profile preview

Erlotinib + Selumetinib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **erlotinib**, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and **selumetinib**, a MEK1/2 inhibitor. Erlotinib is used to treat non-small cell lung cancer and pancreatic cancer, while selumetinib targets the RAS/RAF/MEK/ERK pathway, which is often activated in cancers. The combination aims to enhance anti-tumor activity by targeting multiple pathways involved in cancer cell growth.

Brand names: Tarceva
Other names: Erlotinib Hydrochloride + Selumetinib

Targets

MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on Erlotinib + Selumetinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erlotinib + Selumetinib.

Explore the full profile